{"id":788904,"date":"2023-10-09T07:03:30","date_gmt":"2023-10-09T11:03:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascensia-diabetes-care-and-senseonics-announce-the-cgm-for-real-life-campaign-to-raise-awareness-of-how-long-term-eversense-e3-empowers-people-with-diabetes\/"},"modified":"2023-10-09T07:03:30","modified_gmt":"2023-10-09T11:03:30","slug":"ascensia-diabetes-care-and-senseonics-announce-the-cgm-for-real-life-campaign-to-raise-awareness-of-how-long-term-eversense-e3-empowers-people-with-diabetes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascensia-diabetes-care-and-senseonics-announce-the-cgm-for-real-life-campaign-to-raise-awareness-of-how-long-term-eversense-e3-empowers-people-with-diabetes\/","title":{"rendered":"Ascensia Diabetes Care and Senseonics Announce \u2018The CGM for Real Life\u2019 Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes"},"content":{"rendered":"

<\/p>\n

Ascensia Diabetes Care and Senseonics Announce \u2018The CGM for Real Life\u2019 Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes<\/i><\/b><\/p>\n

Almost 1 in 2 people with diabetes using a short-term CGM are not fully satisfied with their current systemi<\/sup><\/i><\/p>\n

PARSIPPANY, N.J. & GERMANTOWN, Md.–(BUSINESS WIRE<\/a>)–
\nAscensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have launched a new U.S. advertising and marketing campaign for Eversense\u00ae<\/sup> E3 CGM System. \u2018The CGM for Real Life\u2019 campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes. A sample of the new advertising assets can be found here<\/a>.<\/p>\n

\nFor the 37 million people living with diabetes in the U.S.ii<\/sup>, CGM has become an indispensable tool in managing the condition. However, it\u2019s estimated almost half of the people using the two mostly commonly known CGM brands are not fully satisfied with their current systemi<\/sup>. Many people with diabetes take long-term breaks from their CGMs, either because of sensors falling off before expected wear duration or because they don\u2019t want to have something attached to their bodyi<\/sup>. Eversense E3 is the longest lasting CGM available, with 6-month sensor wear duration and two sensor insertion and removal procedures per year. \u2018The CGM for Real Life\u2019 campaign aims to highlight the reality of the diabetes experience, through the everyday complexities, successes, and challenges that people with diabetes face. The campaign demonstrates how Eversense E3 provides a differentiated CGM option, with unparalleled flexibility and long-term use that allows it to seamlessly integrate into real life.<\/p>\n

\n\u201cThis campaign is designed to challenge the status quo in continuous glucose monitoring, which for too long has meant self-insertion and sensors that can either disrupt activities or fall off,\u201d said Rudy Thoms, VP, CGM Commercial U.S. of Ascensia Diabetes Care. \u201cWe know that Eversense has the potential to be game-changing for people with diabetes, and so the opportunity to bring it to the attention of more people than ever before is really exciting.\u201d<\/p>\n

\n\u201cCGMs are often portrayed as one size fits all, but managing diabetes is complex and everyone is different. What works for one person may not work for the next and I personally had a real struggle with short-term CGMs,\u201d said Chris Ruden, Keynote Speaker and Eversense Brand Ambassador. \u201cEversense fits seamlessly into my life and once it\u2019s inserted, I can forget about the hassle of replacements for 6 months. I have a busy life and I don\u2019t want diabetes to get in my way. Thankfully, with Eversense it doesn\u2019t.\u201d<\/p>\n

\n\u2018The CGM for Real Life\u2019 campaign is a coordinated awareness effort delivering information about Eversense E3 directly to U.S. consumers. It is the first time that the brand is launching a campaign across connected TV and linear TV in five states, in addition to digital and social, with the aim to raise awareness of the product\u2019s unique benefits among people with diabetes and healthcare professionals. Senseonics and Ascensia provided an overview of the campaign in a webcast to investors on September 21, 2023. A replay of the webcast is available on the Senseonics website at www.senseonics.com\/investor-relations\/events-and-publications\/events-and-presentations<\/a> (Gilmartin Group Emerging Growth Showcase).<\/p>\n

\nDesigned by Senseonics and brought to patients by Ascensia, the Eversense E3 CGM System offers people with diabetes:<\/p>\n